Thu, Jul 24, 2014, 7:25 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Trius Therapeutics, Inc. (TSRX) Message Board

bionerd51 414 posts  |  Last Activity: 5 hours ago Member since: Jan 2, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Art Kreig….

    by bionerd51 6 hours ago
    bionerd51 bionerd51 5 hours ago Flag

    I've owned AVII/SRPT since the IPO. I've become less active in my posting due to a relocation and issues involving the relocation. I'm very bullish on this company's DMD program

    Sentiment: Strong Buy

  • When he was first hired I posited that it was a terrible hire. He was miscast due to his chemistry background and his exclusive use of RNA-ase dependent oligos. Why would CG hire an interference guy since the PMO is thee steric blocker in this field? His "slow as we go" approach was identical to Iversen's drug development approach which was one of the reasons Iversen was let go. Did CG not question AK about his public comments prior to this hire? With all this said I do believe Kreig tried a "coup" and and then was terminated. When a high profile Officer is terminated after a short term this is very significant and is usually indicative of something more than "moving slow". This same thing went on when Hudson was CEO. He teamed with Forest and tried to take the company from its shareholders.

    Sentiment: Strong Buy

  • Reply to

    Anybody....Jonmolten, bionerd etc...

    by kgrichard5 Jul 11, 2014 10:58 AM
    bionerd51 bionerd51 Jul 11, 2014 11:58 AM Flag

    Rich, An informed guess is one of two possibilities. All supported by comments and preclinical data. First and foremost is the PMO-X platform as it relates to DMD. Researchers at SRPT [past and present] have designed a muscle homing peptide/ arginine delivery peptide that restores 25% of dystrophin body-wide and without appreciable toxicity. The other program is the antiviral/antibacterial platforms. Rumor has it that SRPT has developed a broad spectrum PPMO antibiotic.

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 Jul 10, 2014 10:49 AM Flag

    The 8.5% decline in the 6mwt is disappointing but These boys are 12 y/o. In that context and cognizant of the historical data/ age related decline these results are promising. The FDA was wise in ordering a PhaseIII trial. This drug still receives approval in 2015/16. I'm buying more at these levels.

    Sentiment: Strong Buy

  • Adam F. has a good article on these recycled reports on eteplirsen's putative declining efficacy. Bottomline: it revolves around the 2 twins that were eliminated from treatment/placebo population from analysis due to decline BEFORE treatment began to have effects [24-36 weeks].

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 Jun 27, 2014 8:22 AM Flag

    In SA reporting that Isis's entire 2.0 2MOE platform will have exact toxicity profile as Kynamro. Ouch!..I've been reporting this for over a decade. Don't expect Wall Street to abandon Stan Crooke…Snake Oil salesman

    Sentiment: Strong Buy

  • bionerd51 bionerd51 Jun 23, 2014 1:55 PM Flag

    The European regulatory bodies {MHRA] for drug and biologics will not approve an application without a lawful patent. They might change their minds if approved by the FDA in the U.S. first and if Sarepta can prove that Eteplirsen is a safer and more efficacious drug compared to Drisa.

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 Jun 23, 2014 12:35 PM Flag

    Although there is not a lot written on SRPT's PMO-X program maybe I can shed some light on what specific homing peptide they are using. SRPT's early research in this area of enhanced PMO delivery was in a chimeric peptide which is a combination delivery peptide and muscle specific peptide. The resul;ts were mixed and they discovered that most of this chimeric was ending up in the liver. An improved muscle specific peptide [homing] I believe they are using a 12-mer peptide, M12. It is safe up to 75mg/kgs, it restores 25% of dystrophin in skeletal muscles and very little ends up in the liver. The exact amino acid/polypeptide composition I do not know but it looks like a significant improvement over the PPMO and PMO.

    Sentiment: Strong Buy

  • The ebola outbreak in Western Africa has reach alarming numbers. Anyone can access article[s] on web. I still believe SRPT's ebola antiviral [2 or 3 targets] is better than the competition. This is a real failure of the Bioshield law and DOD.

    Sentiment: Strong Buy

  • Reply to

    Will there be an Isis - Sarepta SMA battle?

    by copphiggins Jun 17, 2014 10:18 AM
    bionerd51 bionerd51 Jun 17, 2014 12:48 PM Flag

    Hong Moulton, biochemist and formerly of AVII was pursuing different conjugated peptide delivery systems coauthored an SMA paper using naked PMO's and Octaguanine[GeneTools] assisted PMO's . Both rescued SMA phenotype via various delivery pathways. I'm convinced based on 18 years of studying this specific oligo field that the PMO will outperform Isis's 2'OME/MOE in this pathology. SRPT is at advantage for this target because of safety, stability and a more efficient W/C binding affinity. Factor Iversen's lab work on manipulating nitrogen bases like guanine-cyto. and adenine-thymine.in translocation of the BBB.

    Sentiment: Strong Buy

  • bionerd51 bionerd51 Jun 13, 2014 12:16 PM Flag

    Jon, I agree with Summerton on oligo cancer targeting. One must target several gene onco transcripts at the same time. One target oligo therapies are doomed to fail. One exception..if one could administer high doses of S-DNAs the toxicity alone might kill cancer cells. I heard Jim was pursuing this area of cancer Tx. [poly-targeting]

    Sentiment: Strong Buy

  • Reply to

    Irrational exuberance about 144 week results?

    by berrybill725 Jun 12, 2014 8:23 AM
    bionerd51 bionerd51 Jun 13, 2014 9:10 AM Flag

    The key to approval under accelerated review/Orphan Drug in this case is that the 10 pts. continue to remain in the stat. sign. zone and the 2 removed [mITT] that were removed from total treatment cohort population is consistent with SRPT's hypothesis that the treatment kicked in to late based on age with these 2 patients and that trend continues in PhaseIII trial data based on similar age and body type. [run on sentence]

    Sentiment: Strong Buy

  • Reply to

    ISIS stock price just moved above SRPT

    by whatmeworriee Jun 10, 2014 10:34 AM
    bionerd51 bionerd51 Jun 10, 2014 12:10 PM Flag

    Love, I have to strongly disagree with you. At therapeutic PMO levels there has been no adverse advents, elevate of liver enzymes which occur daily with the S-DNA's. The only reported toxicity in animal studies that I have seen is when 100X's expected therapeutic dose PMO will accumulate in certain organs and reports of mild granulation in kidneys. By far the safest Oligo in development todays. Only oligo that can be used in live zebrafish for knockdown and up regulation studies. There are more uses in animal models that I won't get into today.

    Sentiment: Strong Buy

  • Reply to

    starfe

    by redlaw9 Jun 8, 2014 11:02 PM
    bionerd51 bionerd51 Jun 9, 2014 11:09 AM Flag

    TKMR's chemistries have very little chance of succeeding in a PhaseIII trial. One could ride the biotech run but once it corrects, watch out TKMR shareholders

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 Jun 6, 2014 8:47 AM Flag

    Journal article highlights the new novel approaches of treating DMD. Eterplirsen rates the most promising. Can't post link but you can access at Current Pediatrics or PUBMED.

    Sentiment: Strong Buy

  • Reply to

    Top line data

    by lou_mangini Jun 5, 2014 8:44 AM
    bionerd51 bionerd51 Jun 5, 2014 11:24 AM Flag

    Micro, I believe this is the first time SRPT has paid to be a top-level sponsor of a Confab. This sounds like very good data will be presented. If not why would they take such a high-profile position in a broker sponsored conference.

    Sentiment: Strong Buy

  • Reply to

    Comparison of Morpholino and 2'-O-Me oligos

    by jonmoulton Jun 3, 2014 5:14 PM
    bionerd51 bionerd51 Jun 4, 2014 1:50 PM Flag

    The chemical characteristics of the PMO have out performed the S-DNA's since the 1990's in organisms, nonhuman primates and as antivirals and antibacterials. The only people who do not know this is the brokerages that follow ISIS and WallStreet

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 May 19, 2014 12:02 PM Flag

    In SA re: Isis and Stan Crooke's BullXXXX. It's amazing what WallStreet will fall for. This is exactly why no one should take oligo advice/ investing biotech from RNAianalyst, a/k/a Dirk H.

    Sentiment: Strong Buy

  • Reply to

    missense therapy

    by musherga May 7, 2014 12:21 PM
    bionerd51 bionerd51 May 7, 2014 12:31 PM Flag

    Another name associated with these types of mutations are polymorphs.

  • Reply to

    missense therapy

    by musherga May 7, 2014 12:21 PM
    bionerd51 bionerd51 May 7, 2014 12:29 PM Flag

    A single "base pair" mutation changes one amino acid in a polypeptide. One base can be skipped over to correct a diseased protein.

TSRX
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.